John Bibb, MD
Medical Oncology · Scottsdale, AZNPI 1881733889
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 40 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 21.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $613 and has fallen 95.8% since, to $25 in 2023. That places this record below the midpoint for medical oncology clinicians in AZ, where the typical reported total is $8,518.
Across 40 payments — averaging $17.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$150
- Eisai Inc.$110
- Merck$67
- E.r. Squibb & Sons, L.L.C.$45
- Lilly USA, LLC$38
- Pfizer$37
- plus $268 from 16 others
What the payments were for
- Food & beverage$713100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 4 | $150 |
| Eisai Inc. | 7 | $110 |
| Merck | 5 | $67 |
| E.r. Squibb & Sons, L.L.C. | 3 | $45 |
| Lilly USA, LLC | 2 | $38 |
| Pfizer | 2 | $37 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $25 |
| Gilead | 2 | $25 |
| Puma Biotechnology, Inc. | 1 | $21 |
| AbbVie | 1 | $21 |
| Boehringer Ingelheim | 1 | $19 |
| Boston Scientific | 1 | $19 |
| Bristol Myers Squibb | 1 | $17 |
| Regeneron Healthcare Solutions, Inc. | 1 | $17 |
| Sun Pharmaceutical Industries Inc. | 1 | $16 |
| Amgen | 1 | $16 |
| Dova Pharmaceuticals | 1 | $15 |
| Genentech USA, Inc. | 1 | $12 |
| Sandoz | 1 | $12 |
| Johnson & Johnson | 1 | $11 |
| Advanced Accelerator Applications | 1 | $11 |
| Teva Pharmaceuticals USA, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LEMTRADA$104
How this compares
$713 in reported general payments places this provider in the 20th percentile of 59 medical oncology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PomalystPomalidomide | 66 | $1,467,339 |
| RevlimidLenalidomide | 43 | $687,876 |
| Lenalidomide | 31 | $439,150 |
| CalquenceAcalabrutinib Maleate | 25 | $379,954 |
| NinlaroIxazomib Citrate | 26 | $333,101 |
| PegasysPeginterferon Alfa-2a | 20 | $84,837 |
| EliquisApixaban | 92 | $82,782 |
| XareltoRivaroxaban | 74 | $75,745 |
| Abiraterone Acetate | 21 | $5,222 |
| Enoxaparin Sodium | 20 | $3,780 |
| Letrozole | 46 | $1,109 |
| Acyclovir | 46 | $954 |
| Dexamethasone | 45 | $928 |
| Anastrozole | 49 | $796 |
| Hydroxyurea | 33 | $759 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Pomalyst | $45 | $1,467,33966 claims |
| Bristol Myers SquibbRevlimid | $17 | $687,87643 claims |
| PfizerEliquis | $37 | $82,78292 claims |
| Johnson & JohnsonXarelto | $11 | $75,74574 claims |
| SandozEnoxaparin Sodium | $12 | $3,78020 claims |
| Teva Pharmaceuticals USA, Inc.Acyclovir | $11 | $95446 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 59 medical oncology providers in Arizona.
Other medical oncology in Scottsdale
- Daniel von HoffScottsdale$165K
- Erkut BorazanciScottsdale$31K
- Rajinder GroverScottsdale$13K
- Rishi AgarwalScottsdale$12K
- Walter KimScottsdale$6K
- Ashish ChintakuntlawarScottsdale$2K
- Jason SalganickPhoenix$1.6M
- Roopesh KantalaMesa$491K
- Nazish AhmadGlendale$205K
- David KahnSurprise$47K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.